February 12, 2018 / 3:13 PM / 5 months ago

BRIEF-Pulmatrix Announces First Subject Dosed In Phase 1 Clinical Trial Of Pulmazole

Feb 12 (Reuters) - Pulmatrix Inc:

* PULMATRIX ANNOUNCES FIRST SUBJECT DOSED IN PHASE 1 CLINICAL TRIAL OF PULMAZOLE - AN INHALED DRY-POWDER ISPERSE™ FORMULATION OF ITRACONAZOLE

* PHASE 1 DATA FOR CLINICAL TRIAL OF PULMAZOLE IS EXPECTED IN MID-2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below